POST Online Media Lite Edition



 

NEWLY REPORTED COVID-19 CASES IN LAST 24 HOURS (6.15.2021, 11:19am CEST, WHO):   U.S. 8,197    India 70,421    Brazil 37,948    France 2,850    Turkey 5,012    Russia 13,721    The United Kingdom 7,319    Italy 1,390    Argentina 13,043    Columbia 28,519    Iran 10,715    Mexico 1,707    Peru 2,566    Indonesia 8,189    South Africa 7,657    The Netherlands 1,066    Chile 6,190    Canada 1,120    Philippines 6,426    Iraq 5,040    Pakistan 1,019    Bangladesh 3,050    Japan 1,076    Malaysia 4,949    Nepal 2,049    United Arab Emirates 1,837    Saudi Arabia 1,109    Bolivia 1,607    Paraguay 1,786    Panama 1,573    Tunisia 1,316    Uruguay 2,043    Kuwait 1,563    Venezuela 1,377    Oman 1,806    Sri Lanka 2,284    Thailand 3,355    Cuba 1,349    Zambia 1,414    Afghanistan 1,814    Mongolia 2,263    Uganda 1,727    China 206    Singapore 25    New Zealand 1    Australia 14    South Korea 374   

Medicine to prevent patients from developing coronavirus tested in UK

Christian Fernsby |
A medicine that can potentially prevent people exposed to novel coronavirus from developing coronavirus is now being tested in the United Kingdom, the Guardian reported.

Article continues below




The medicine, based on monoclonal antibodies created in a laboratory, was developed by AstraZeneca and the University College London Hospitals.

"If we can prove that this treatment works and prevent people who are exposed to the virus going on to develop coronavirus, it would be an exciting addition to the arsenal of weapons being developed to fight this dreadful virus," said Dr Catherine Houlihan, a UCLH virologist who is leading a study into the drug.

Scientists hope that people from high-risk groups will be protected from coronavirus for a period of between six months and one year. It is also expected to be effective in cases when vaccination is too late, for example if offered to someone after close contact with a virus carrier.

Developers expect the medicine to hit shelves in the UK in March or April 2021, if clinical trials are successful and it is approved by the country’s healthcare regulators.


What to read next

Research team eradicates hepatitis C transplants from infected donors
Deadly heart rhythm halted by noninvasive radiation therapy
Hospitals that sends heart patients to ICU have worst results